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Obesity is a serious health problem with an increased risk of several common diseases including diabetes, cardiovascular disease,
and cancer. Metabolomics is an emerging analytical technique for systemic determination of metabolite proﬁles, which is useful
for understanding the biochemical changes in obesity or related diseases both in individual organs and at the organism level.
Increasingly, this technology has been applied to the study of obesity, complementing transcriptomics and/or proteomics analyses.
Indeed, the alterations of metabolites in bioﬂuids/tissues are direct indicators of variations in physiology or pathology. In this
paper, we will examine the obesity-related alterations in signiﬁcant metabolites that have been identiﬁed by metabolomics as well
as their metabolic pathway associations. Issues concerning the screening of biologically signiﬁcant metabolites related to obesity
will also be discussed.
1.Introduction
Obesity is characterized by abnormal or excessive fat accu-
mulation that is the result of a chronic imbalance between
energy intake and energy expenditure [1, 2]. It poses a
substantialhealthrisk,asobesityislinkedtoseveralcommon
diseases, such as type 2 diabetes, cardiovascular disease,
stroke, arthritis, and several types of cancer [3]. Obesity can
behighlyheritable,andsomespeciﬁcgenesrelatedtoobesity
have been identiﬁed [4]. However, over the past decade, the
prevalence of obesity in the world has dramatically increased
across all age groups, especially in developed countries [5],
so that genetic factors alone cannot explain the obesity
epidemic. It is widely agreed that obesity is a complex
multifactorial disease involving genetic, environmental, and
lifestyle factors [6] and it is necessary to investigate the mode
of action of each contributing factor in order to reduce the
associated health risks.
Metabolomics is a newly emerging bioanalytical tech-
nique similar in scope to genomics and proteomics that uses
analytical techniques such as nuclear magnetic resonance
(NMR) spectroscopy or mass spectrometry (MS) to charac-
terize and quantify all small molecules in biological samples
to achieve comprehensive global monitoring of metabolites
and their ﬂuctuations in response to various stimuli [7, 8].
Therefore, metabolomic data can provide the information
on what is actually happening in a biological system, serving
as the crucial link between phenotype and genetics. To date,
metabolomics has demonstrated enormous potential in fur-
theringtheunderstandingofdiseaseprocesses[9],toxicolog-
ical mechanisms [7, 10], biomarker discovery [11], and gut
microbiome-host variations [12, 13]. Obesity is a disorder of
the whole body and obviously involves metabolic changes,
but the actual alterations in metabolism during obesity
and any dysfunction associated with obesity at the level of
individual organs or cellular organelles are not yet clearly
understood [2]. As metabolomics can readily detect subtle
changes in the metabolic network, it is uniquely poised to
increase our understanding of obesity and obesity-related
diseases.
Animal models have provided a fundamental contribu-
tiontotheinvestigationoftheonsetandprogressionofcom-
plex multifactorial diseases such as obesity [14]. The greatest
advantage of animal models is that they allow strict control
of factors such as diet, environmental conditions, or genetic
background. Thus, animal models have been widely used2 Journal of Biomedicine and Biotechnology
in metabolomics for exploring the metabolic changes and
potential biochemical mechanisms of obesity development.
The general process of a metabolomics study includes
appropriate design and sampling of experimental study co-
horts, selection of analytical technique (NMR spectroscopy
and/or MS), data preprocessing and statistical analysis, iden-
tiﬁcation of candidate biomarkers, and elucidation of their
biological relationship. How to obtain metabolic proﬁles
from biological ﬂuids and how to analyse metabolomic
data will not be discussed in detail in this paper as these
topics have been thoroughly reviewed elsewhere [7, 15–
17]. We will focus here on individual signiﬁcant metabolites
and metabolic pathways related to obesity which have been
identiﬁed by metabolomics.
2.Investigationof Obesity-Associated
Metabolitesby Metabolomics
Recently, many obesity-related metabolites have been iden-
tiﬁed by metabolomics and demonstrated to be disturbed
signiﬁcantly in both animal models and humans. Table 1
and Figure 1 show a summary of these metabolites and their
relationships in metabolic pathways, respectively. We will
discuss several of these metabolites in more detail below.
2.1. Metabolites Related to Glucose Metabolism and Tricar-
boxylic Acid (TCA) Cycle. Glucose is a key source of energy
for most organisms. It is catabolised via glycolysis to pyru-
vate, which under aerobic conditions is converted into acetyl
coenzyme A (AcCoA), the entry point into the TCA cycle.
Under anaerobic conditions, pyruvate is instead converted to
lactate by the enzyme lactate dehydrogenase. It was found
that the concentration of lactate in urine, blood, or liver
tissue is elevated in obese mice induced by high-fat diet
(HFD), or in obese Zucker rats lacking the leptin receptor,
compared to their lean controls (Table 1)[ 18–22]. One study
found lower lactate levels in the urine of obese Zucker
rats, but this decrease was only small compared to other
metabolite changes and could have been caused by small
cohort sizes [23]. The ﬁndings of generally higher lactate
levels in obese Zucker rats are consistent with higher blood
lactate levels in obese humans measured by conventional
methods [24]. It was presumed that the elevation of lactate
in obese animals was the result of upregulated anaerobic
glycolysis when compared to lean controls [18, 19]. The
blood concentration of lactate is largely determined by the
balance of the rate of lactate production (which mainly takes
place in skeletal muscle, the erythrocytes, brain [25], and
adiposetissue[26])relativetotherateofitsremovalbyother
tissues or by urinary excretion. Importantly, subcutaneous
fat was demonstrated to be a signiﬁcant source of lactate;
therefore, obese subjects have a greater apparent lactate
release due to their larger adipose mass, and a higher plasma
lactate than lean individuals [26]. Lactate is also the major
precursor for gluconeogenesis in the body, and the rise in
plasma lactate in obesity may be an indicator of perturbation
of hepatic glucose production and hepatic lipid synthesis.
Thus, lactate is an important obesity-related metabolite
identiﬁed by metabolomics.
Under aerobic conditions, pyruvate enters the TCA cycle
via AcCoA to produce energy via formation of citrate,a n d
other TCA cycle metabolites. It was reported that inhibition
of citrate metabolism by ﬂuoroacetate, a chemical inhibitor,
reduced body fat in mice [27]. Next to glucose catabolism,
AcCoA and consequently citrate are in animals also gener-
ated by fatty acid oxidation. The concentration of citrate
in plasma is regulated by insulin, glucose levels, fatty acid
utilization, cholesterol synthesis, liver clearance and renal
excretion [28]. Blood citrate was found to be increased
in alloxan-induced diabetic rats [29], and lowered upon
insulin administration in experimental animal models [30]
and children [31]. Similarly, higher serum concentrations
of citrate when compared to their controls were detected
by NMR [28] or gas chromatography-MS (GC-MS) [32]
based metabolomics in HFD-fed obese animals with insulin
resistance. Conversely, lower urinary citrate excretion was
reported to be associated with a higher level of insulin
resistance in humans [33], and depletion of urinary citrate
excretion was reported in obese animals with insulin resis-
tance [32], while the opposite was seen in obese animals
without insulin resistance [20]. Depletion of urinary citrate
excretion was also found in obese animals, with truncations
in the intracellular domain of the growth hormone receptor
(GHR) [34, 35]. Urinary citrate excretion is inﬂuenced by
the acid-base status of the body [36], with alkalosis inducing
an increase in urinary citrate excretion, and acidosis having
the opposite action. Obesity, especially in conjunction with
insulin resistance, can increase metabolic acidosis and thus
result in a reduction of urinary citrate excretion [37]. Thus,
citrate can be used as a marker related to insulin or glucose
levels in metabolic studies.
2.2. Metabolites Related to Lipid Metabolism. Lipids are an
important source and store of energy for metabolism. Blood
lipids, derived from food intake or adipose tissue and
liver, are mainly fatty acid derivatives and cholesterol. High
concentrations of fatty acids or cholesterol in blood have
been used as an indicator of disease risk, as their alteration
is related to some cardiovascular diseases, such as coronary
heart disease, diabetes [38, 39], and hypertension [40]. In
liver and muscle, free fatty acids (FFAs) are catabolised in the
mitochondria to produce energy through β-oxidation and
the TCA cycle, whereas excess lipids are stored in adipose tis-
sueandelsewhereastriglycerides[41].Obesity,characterized
by fat deposits in tissue, is generally associated with elevated
levels of plasma FFAs [42]. In agreement with this, elevation
of FFAs in serum and liver of obese animals has been
observed by metabolomic analysis (Table 1). Furthermore,
the serum FFA composition, especially the proportion of
saturated fatty acids (SFAs), has been found to be positively
associatedwiththedevelopmentofobesityanddiabetes[43].
Incontrast,lowerlevelsofessentialfattyacidssuchaslinoleic
acid were found in circulating lipids of obese patients [44].
Compared to conventional targeted analysis of FFAs,
metabolomics can provide a more unbiased relationship ofJournal of Biomedicine and Biotechnology 3
Table 1: Metabolite changes in obesity.
Pathway Metabolitea Model/sampleb Analytical platform Reference
Glucose metabolism and TCA cycle Lactate (+) HFD rat/urine 1HNMR [20]
HFD mouse/serum 1HNMR [19]
Zucker rat/liver, blood 1HNMR [18]
Zucker rat/urine, blood 1HNMR [21]
LDLr mouse/liver 1HNMR [22]
Lactate (−) HFD mouse/serum 1HNMR [56]
Zucker rat/urine 1HNMR [23]
Acetate (+) Zucker rat/ blood 1HNMR [18]
Zucker rat/urine 1HNMR [21]
Acetate (−) HFD mouse/serum 1HNMR [28]
HFD mouse/urine 1HNMR [55]
HFD mouse/serum 1HNMR [56]
Citrate (+) HFD mouse/serum 1HNMR [28]
HFD rat/urine 1HNMR [20]
HFD rat/serum GC-MS [32]
Citrate (−) HFD rat/urine GC-MS [32]
Zucker rat/urine 1HNMR [23]
M391 mouse/urine 1HNMR [34]
Pyruvate (+) HFD rat/urine 1HNMR [20]
HFD mouse/serum 1HNMR [19]
Succinate (+) HFD mouse/serum 1HNMR [19]
HFD rat/liver GC-MS [32]
2-Oxoglutarate (−) M391 mouse/urine 1HNMR [34]
Lipid metabolism Fatty acid (+) HFD rat/liver, serum GC-MS [32]
Zucker rat/liver 1HNMR [18]
HFD mouse/liver LC (GC)-MS [42]
Human/blood UPLC-MS [46]
Taurine (+) HFD rat/urine 1HNMR [20]
HFD mouse/liver 1HNMR, LC-MS [54]
HFD mouse/liver 1HNMR [55]
HFD mouse/serum 1HNMR [19]
HFD mouse/liver 1HNMR [34]
Zucker rat/urine 1HNMR [23]
Taurine (−) HFD mouse/serum 1HNMR [56]
Zucker rat/urine UPLC-MS [53]
M391 mouse/liver, urine 1HNMR [34]
Zucker rat/urine 1HNMR [21]
Carnitine (+) HFD mouse/serum LC (GC)-MS [42]
Carnitine (−) HFD mouse/liver LC (GC)-MS [42]
Human/blood UPLC-MS [46]
PCs (+); lysoPCs (−) HFD mouse/serum, liver LC (GC)-MS [42]
Choline metabolism Choline (+) HFD mouse/liver 1HNMR, LC-MS [54]
Zucker rat/blood 1HNMR [21]
Zucker rat/urine 1HNMR [23]
Betaine (+) HFD rat/urine 1HNMR [20]
Betaine (−) HFD mouse/liver LC (GC)-MS [42]
Zucker rat/liver 1HNMR [18]
Zucker rat/urine 1HNMR [21]
TMAO (−) HFD mouse/serum 1HNMR [28]
HFD mouse/urine 1HNMR [55]
HFD mouse/serum 1HNMR [56]
Zucker rat/urine 1HNMR [21]4 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Pathway Metabolitea Model/sampleb Analytical platform Reference
TMAO (+) M391 mouse/urine 1HNMR [34]
TMA (+) M391 mouse/urine 1HNMR [34]
TMA (−) HFD mouse/urine 1HNMR [55]
Sarcosine (+) HFD mouse/liver NMR, LC-MS [54]
Hippurate (−) HFD mouse/serum 1HNMR [28]
Human/urine 1HNMR [97]
Amino acid metabolism BCAA (+) Human/blood UPLC-MS [46]
HFD rat/liver GC-MS [32]
BCAA (−) HFD mouse/serum 1HNMR [28]
HFD mouse/urine 1HNMR [55]
HFD mouse/liver LC (GC)-MS [42]
HFD mouse/serum 1HNMR [56]
HFD rat/urine GC-MS [32]
Methionine (+) Zucker rat/liver 1HNMR [18]
Methionine (−) HFD mouse/liver 1HNMR, LC-MS [54]
HFD mouse/serum 1HNMR [56]
Glycine (−) HFD mouse/liver 1HNMR, LC-MS [54]
Zucker rat/blood 1HNMR [21]
HFD rat/liver,serum GC-MS [32]
Serine (−) HFD mouse/liver 1HNMR, LC-MS [54]
Alanine (+) HFD mouse/serum LC (GC)-MS [41]
HFD rat/liver,serum GC-MS [32]
Tyrosine (+) Human/blood UPLC-MS [45]
HFD mouse/serum LC (GC)-MS [41]
HFD rat/urine GC-MS [32]
Tyrosine (−) HFD rat/liver GC-MS [32]
Lysine (−); Arginine (−) HFD mouse/serum 1HNMR [28]
Phenylalanine (−) HFD mouse/urine 1HNMR [55]
Glutamate (−) Zucker rat/blood 1HNMR [21]
Creatine metabolism Creatinine (+) M391 mouse/urine 1HNMR [34]
HFD mouse/urine 1HNMR [55]
Creatine (+) HFD mouse/serum 1HNMR [19]
M391 mouse/urine 1HNMR [34]
Zucker rat/urine 1HNMR [23]
Uric acid (+) HFD mouse/serum LC (GC)-MS [42]
a(+) and (–) indicate an increase or decrease in relative metabolite concentration, respectively, when comparing obesity with control.
b“Model” denotes the genetic or dietary cause of obesity, “sample” denotes the type of biological sample.
FFAstoothersmallmolecules,whichmayhelptounderstand
obesity. For example, based on ultraperformance liquid
chromatography quadrupole time-of-ﬂight (UPLC Q-TOF)
MS and GC-MS, higher levels of stearic acid, total SFAs and
palmitoleic acid and lower linoleic acid levels, as well as
the variation of amino acids and carnitine in plasma, were
detected in overweight/obese men [45].
Carnitine is a key metabolite related to obesity, due to its
involvement in fatty acid metabolism. It is well documented
that provision of FFAs can promote fatty acid oxidation
[46]. However, fatty acids can only produce energy via β-
oxidation after esteriﬁcation and transport into the mito-
chondrion with the help of carnitine [47]. Thus, higher
plasma FFAs in obesity may require more carnitine for
eﬃcient β-oxidation. Consequently, the amount of carnitine
in cells is an important factor regulating the process of β-
oxidation. Indeed, it has been reported that supplementation
of carnitine can diminish the risk of obesity caused by a
HFD in C57BL/6J mice [48], and carnitine is popularly used
as a weight loss product [49]. Consistent with this picture,
depletion of carnitine levels was observed in liver tissue of
o b e s em i c e[ 41] or blood samples of obese humans [45]. The
decreased carnitine levels in obesity could be insuﬃcient for
β-oxidation to compensate the elevation of FFAs, and as a
result, contribute to fat accumulation in adipose tissue.
Taurine is an important metabolite in bile acid meta-
bolism and has many important biological roles such as
conjugation of cholesterol and bile acids, antioxidation,Journal of Biomedicine and Biotechnology 5
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Figure 1: The relationship of obesity-related metabolites in the metabolic network. Metabolites explicitly mentioned in this paper are
indicated in boxes and italics. BCAA, branched chain amino acids; TMAO, trimethylamine N-oxide.
osmoregulation, and modulation of calcium signaling [50].
In a rat model of type 2 diabetes, a taurine-supplemented
diet tended to decrease total fat weight in the abdominal
cavityandimprovedinsulinsensitivity[51].Similarly,Zhang
et al. reported that taurine supplementation signiﬁcantly
decreased serum lipids and body weight in obese individuals
[52]. Based on 1H-NMR spectroscopy and microarray tech-
niques, signiﬁcant depletion of hepatic and urinary taurine,
as well as lower expression of cysteine sulﬁnic acid dehy-
drogenase (Csad) in GHR mutant obese mice, was observed
when compared with wild-type mice in our previous work
[34]. The ﬁndings indicated that lower urinary taurine
levels in the mutant mice can reﬂect lower hepatic taurine
biosynthesis in GHR mutant mice. Lower urinary excretion
of taurine was also reported in obese Zucker rats [21,
53]( Table 1). These observations indicate that a decreased
production of taurine in liver due to inhibition of taurine
biosynthetic enzymes is closely related to obesity.
Interestingly, we found that the hepatic taurine level in
liver was increased signiﬁcantly when wild-type mice were
fed an HFD [34]. Recently, Rubio-Aliaga et al. [54]c o n -
ﬁrmed that not only elevation of hepatic taurine, but also
depletion of the expression of two key enzymes involved in
taurine biosynthesis, cysteine dioxygenase (CDO) and Csad,
was observed in HFD-induced obesity mice. Similar results
of elevated taurine levels in liver extracts but decreased
urinary taurine were also found in another study on HFD-
fed obese mice [55].
In vivo, taurine in liver is supplied from blood by dietary
ingestion as well as from de novo synthesis. It is likely that the
elevation of hepatic taurine and the decreased production
of biosynthesized taurine in obesity induced by HFD are
associated with depletion of the blood taurine concentra-
tions. This was conﬁrmed in a recent metabolomic study for
HFD-induced mice [56] and obese humans in comparison
with age- and sex-matched nonobese subjects [57]. Indeed,
Tsuboyama-Kasaoka et al. [58] not only found that blood
taurine concentrations were decreased in HFD-induced
obese mice, but also that dietary taurine supplementation
could reverse the obesity induced by HFD. They proposed
a role for taurine as a metabolite able to increase fatty
acid oxidation and decrease obesity. In the light of this, the
increasedprovisionoffattyacidsinobesitymayrequiremore
taurine to promote fatty acid oxidation. Thus, the obesity in
theGHRmutantmiceislikely tobe aconsequenceofthelow
taurine levels, whereas the elevation of hepatic taurine seen
in HFD-fed wild-type mice is a compensatory mechanism
to overcome the increased supply of dietary triglycerides
by promoting β-oxidation [34]. These observations indicate
that taurine should be a focus of further investigation with
respect to the mechanism of the onset and development of
obesity.
2.3. Metabolites Related to Choline Metabolism. Choline is an
essential dietary nutrient that is important for integrity
of cellular structure, methyl (one-carbon) metabolism, and
lipid/cholesterol transport and metabolism [59, 60]. In
animals, over 95% of the total choline pool in most tissues
is used for the synthesis of phosphatidylcholine (PC) via6 Journal of Biomedicine and Biotechnology
the Kennedy pathway [61]. In HFD-fed obese mice the
hepatic and serum PC was increased compared to normal
controls [41]. In the mitochondria of liver and kidney,
choline can be oxidized to betaine, whose methyl groups
are used to synthesize methionine from homocysteine [62].
It was presumed that betaine plays a key role in fatty
acid metabolism related to carnitine production [41, 63].
Metabolomic analysis revealed depletion of betaine in the
liver of HFD-induced obese mice [41] and Zucker rats [18]
which may result in a decreased hepatic carnitine level, and
eventually lead to decreased β-oxidation and increased fatty
acid storage. Indeed, a lower hepatic carnitine level was
detected by LC(GC)-MS in HFD-fed obese mice [41].
In mammals, choline is derived not only from diet, but
also from de novo synthesis. During HFD intervention, hep-
atic one-carbon metabolism and related pathways are altered
signiﬁcantly. For example, higher hepatic choline levels and
lower hepatic methionine concentrations were found in an
HFD mouse model [54]. It was suggested that the higher
hepatic choline levels were used for synthesizing essential
amino acids such as methionine and that these alterations
would play an important role in the development of insulin
resistance and liver steatosis [54].
However, the amount of choline supplied by de novo
biosynthesis may be not adequate to meet the demand for
choline to maintain health [59]. Indeed, feeding animals a
methionine- and choline-deﬁcient (MCD) diet can result in
fattyliver,whichissimilartohumannonalcoholicsteatohep-
atitis (NASH), and MCD diet is a frequently used nutritional
model of NASH [64, 65]. The mechanism of development of
hepatic steatosis induced by MCD diet in mice presumably
involves an increase of fatty acid uptake and decrease of
very low-density lipoprotein (VLDL) secretion, which would
promote intrahepatic lipid accumulation [66].
The pathway from dietary PC/choline to trimethy-
lamine (TMA) and trimethylamine N-oxide (TMAO) has
been known since the 1950s [67]. Recently, Wang et al.
[13] crucially demonstrated that intestinal microﬂora are a
key element in this pathway and thus in the generation of
TMA from dietary choline in vivo. The importance of gut
microbiota for TMA production from its precursor choline
was also demonstrated with germ-free mice experiments
[68]. Thus, metabolites such as TMA and TMAO are direct-
ly indicative of gut microbiota status. By combining 1H
NMR spectroscopy and multivariate statistical techniques,
Dumas et al. [12] found a signiﬁcant association between
variations in choline metabolism—for example, low plasma
PC and high urinary methylamines (dimethylamine, TMA,
TMAO)—and genetic predisposition to HFD-induced non-
alcoholic fatty liver disease in mice. Based on this, Dumas et
al.proposedadiet-inducedmechanismofsteatosis,triggered
by symbiotic microbiota, which mimic choline-deﬁcient
diets [12]. Indeed, gut microbiota have been demonstrated
to be able to inﬂuence the eﬃciency of harvesting energy
fromdietandconsequentlyinﬂuencesusceptibilitytoobesity
[69]. Several metabolomic studies show depletion of serum
or urinary TMAO in HFD-induced obese mice or Zucker
rats (Table 1), whereas, elevation of TMAO was observed in
GHR mutant obese mice [34]. In addition, urinary excretion
of microbiota-derived metabolites was found to vary signif-
icantly depending on the mouse strain [12], underlining the
importance of gut microbiota in nutrient supply.
2.4. Metabolites Related to Amino Acid Metabolism. Amino
acids that were shown to display signiﬁcant obesity-related
variations are listed in Table 1. The branched chain amino
acids (BCAAs), leucine, isoleucine,a n dvaline, are among the
nine essential amino acids for humans. The BCAAs play
important roles in protein synthesis [70], improve glucose
metabolism and oxidation [71], and regulate leptin secretion
from fat and food intake [72]. BCAA supplementation
was found to beneﬁcial for patients undergoing chemoem-
bolization to improve postoperative nutritional status [73].
In mouse models, very low blood levels of BCAAs were
associated with neuropathology, including the development
ofepilepticseizures[74].However,highlevelsofBCAAshave
been reported in obese persons, and fasting concentrations
of branched-chain and aromatic amino acids were correlated
with obesity and serum insulin levels [75, 76]. Based
on metabolic proﬁling of obese versus lean humans and
data obtained from rats on diﬀerent diets, Newgard et al.
[24] demonstrated that BCAAs did contribute to obesity-
related comorbidities such as insulin resistance and glucose
intolerance. Furthermore, a recent study showed that the
blood concentration of ﬁve branched-chain and aromatic
amino acids (isoleucine, leucine, valine, tyrosine, andpheny-
lalanine) could predict the risk of future diabetes [77]. In
agreement with this, plasma levels of valine and leucine were
23% and 14% higher, respectively, in overweight/obese male
humans compared to the lean controls [45]. In contrast,
some previous studies [78, 79] failed to demonstrate the
elevation of blood BCAA levels in obese patients, but this
m a yh a v eb e e nc a u s e db yad i ﬀerent dietary regimen in the
obese subjects [79, 80]. Similarly, depletion of serum levels
of BCAAs was reported in HFD-fed obese mice in other
metabolomic studies [28, 56]. An HFD with lower protein
content [28] may decrease the supply of BCAAs.
On the other hand, obesity may play a role in the regula-
tion of BCAA catabolism. In animals, BCAAs are presumed
to be degraded in muscle and adipose tissue rather than in
the liver [81],and a recentstudy indicated that adipose tissue
may make a more important contribution to the whole body
BCAA metabolism [82]. It was reported that the activities
of the mitochondrial branched chain amino acid amino-
transferase and branched chain α-ketoacid dehydrogenase
enzyme complex, the key enzymes in the catabolic pathway
of BCAAs, were depressed in adipose tissue of obese ob/ob
mice and Zucker rats, leading to increased BCAA levels
[82]. Apart from the elevation of BCAAs in plasma, blood
C3 and C5 acylcarnitine levels were observed to increase
signiﬁcantly in obesity [24]. In agreement with this, higher
levels of propionyl-, butyryl-, and hexanoylcarnitines in
obese male humans have been detected by metabolomics
analysis [45]. Indeed, C3 acylcarnitines are a byproduct of
both isoleucine and valine catabolism, and C5 acylcarnitines
are intermediates in mitochondrial isoleucine and leucine
catabolism[24].Inaddition,elevationofbloodpyruvateandJournal of Biomedicine and Biotechnology 7
alanine levels (Table 1)—both metabolites related to BCAA
catabolic pathways—could contribute to development of
glucoseintoleranceinobesity[24].Thesemetabolitechanges
may imply an overload of BCAA catabolism in obesity,
caused by forcing the now expanded circulating BCAA pool
to divert away from protein synthesis and into catabolic
pathways [24].
A recent metabolomic study reported that both blood
glutamine and glycine were signiﬁcantly decreased in obese
individualswhencomparedtotheirleancontrols[83],which
is consistent with the results of a previous study [84]. Both
glutamine and glycine are nonessential amino acids that can
be synthesized in the body. Glutamine is the most abundant
amino acid in plasma [83], and glutamate, the precursor of
glutamine, can be derived from 2-oxoglutarate in the TCA
cycle [85]. Glycine can be generated from serine, an amino
acid derived from pyruvate. Early experiments with 15N-
labeled amino acids demonstrated thatabout50% of the uri-
nary ammonia is normally derived from the amide nitrogen
and 16∼25% from the amino nitrogen of plasma glutamine
[86]. It has been reported that oral administration of glycine
or glutamine is associated with a signiﬁcant increase in the
rate of urea synthesis, and administration of glycine results
in a small increase in glutamine turnover in infants [87].
Thus, glutamine and glycine are important precursors for
urea biosynthesis. In addition, as both glutamine and glycine
arerelatedtoglucosemetabolism,thedepletionofglutamine
or glycine in blood in obesity may lead to the dysfunction of
cells [85].
2.5. Creatine Metabolism. Endogenous creatinine is a break-
down product of creatine in muscle, which is biosynthesized
from arginine and glycine [88]. In vivo, creatinine is usually
produced at a fairly constant rate proportional to muscle
mass, and then ﬁltered from the blood by the kidneys. How-
ever, previous studies showed increased urinary excretion
of creatinine in obese individuals during a 4-hour or 24-
hour period [89]. Similar results were observed in HFD-
fed obese mice and obese GHR mutant mice (Table 1). The
reason for this may be related to skeletal and cardiac muscle
hypertrophy to support and move the increased body mass
[89], endogenous biosynthesis pathways, kidney function, or
all of these [34].
In kidney, the excretion of creatinine is chieﬂy deter-
mined by glomerular ﬁltration and proximal tubular secre-
tion since virtually no creatinine is reabsorbed in the nephric
tubule. Therefore, creatinine levels in blood and urine may
be used to calculate the creatinine clearance, which usually
reﬂects renal function in clinic [90]. It was reported that
glomerular ﬁltration rate and renal plasma ﬂow exceeded the
normal value by 51 and 31%, respectively, in nondiabetic
subjects with severe obesity [91]. However, as indicated, obe-
sity is associated with insulin resistance, hypertension, and
dyslipidemia [89]. These metabolic abnormalities pose a
higher risk for kidney diseases, which decreases creatinine
clearance[92,93],asdoesaging[94],thuscautionisrequired
in interpreting changes in creatinine clearance in obesity and
diabetes.
3. Discussion
Metabolomics as a tool for determining biochemical proﬁles
has in recentyears beenincreasingly employed forinvestigat-
ingobesityandrelateddiseases.Withtechnologicalimprove-
ments in sensitivity and resolution, especially in multihy-
phenated NMR and MS, an increasingly large number of
metabolites can be reliably detected and identiﬁed simulta-
neously in bioﬂuids and tissue. In addition, integration and
correlation of data derived from diﬀerent bioﬂuids, such as
urine, plasma or tissues, and even of other “omics” data,
can be achieved through new bioinformatic approaches [95].
These are expectedto facilitatethe development of metabolic
models to understand the alterations of metabolism during
obesity and related diseases such as type 2 diabetes. Based
on the examples presented in this review, it is evident that
metabolomics, especially when integrating multiple detect-
ing techniques or using a multiomics approach, is a useful
tool for investigating obesity. The information generated by
metabolomic analysis provides us with increased knowledge
as to how the metabolic network is perturbed during obesity.
However, dietary inﬂuence is a major issue that should
be taken into consideration in metabolomics when relating
changes in biologically signiﬁcant metabolites to obesity. It
has been reported that the most recent diet can strongly
aﬀect the serum proﬁle of mice, particularly with respect to
energy metabolism and glucose utilization, despite fasting
prior to serum collection [19]. HFD-fed animal models
are widely used for studying environmental inﬂuences re-
sulting in obesity [10, 96]. However, the modiﬁed nutrient
composition of HFD with a high content of fat (59%,
21% for standard diet) [28] and lower protein availability
may instantly change the bioﬂuid proﬁles such as amino
acids, even before obesity occurs, because the levels of many
metabolites derive from the balance of de novo synthesis,
dietary supplement, and urinary excretion. In addition, it
was found that the food intake of obese mice induced by
HFD was decreased approximately 10% [41]. Therefore, in
metabolomic analysis the eﬀect of diet needs to be taken into
accounttoobtainthemetabolitealterationsrelatedtoobesity
rather than to diet changes.
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